Li Yuefeng, Li Zhian
Department of Oncological Surgery, Shaoxing Second Hospital, Shaoxing, China.
Front Oncol. 2021 Mar 18;11:629614. doi: 10.3389/fonc.2021.629614. eCollection 2021.
Breast cancer incidence and mortality rates have been consistently high among women. The use of diverse therapeutic strategies, including chemotherapy, endocrine therapy, targeted therapy, and immunotherapy, has improved breast cancer prognosis. However, drug resistance has become a tremendous obstacle in overcoming breast cancer recurrence and metastasis. It is known that mitochondria play an important role in carcinoma cell growth, invasion and apoptosis. Recent studies have explored the involvement of mitochondrial metabolism in breast cancer prognosis. Here, we will provide an overview of studies that investigated mitochondrial metabolism pathways in breast cancer treatment resistance, and discuss the application prospects of agents targeting mitochondrial pathways against drug-resistant breast cancer.
乳腺癌的发病率和死亡率在女性中一直居高不下。包括化疗、内分泌治疗、靶向治疗和免疫治疗在内的多种治疗策略的应用改善了乳腺癌的预后。然而，耐药性已成为克服乳腺癌复发和转移的巨大障碍。众所周知，线粒体在癌细胞的生长、侵袭和凋亡中起重要作用。最近的研究探讨了线粒体代谢与乳腺癌预后的关系。在此，我们将概述研究线粒体代谢途径在乳腺癌治疗耐药性中的作用的相关研究，并讨论针对线粒体途径的药物在治疗耐药性乳腺癌方面的应用前景。
